|Trade names||Axid, Tazac|
|Elimination half-life||1–2 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||331.46 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals. Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA). However, a year later, they sold rights of the Axid Oral Solution (including the issued patent protecting the product) to Braintree Laboratories.
- Famotidine (Pepcid) — another popular H2 receptor antagonist
- "Nizatidine". Livertox.nih.gov. Retrieved 2015-10-11.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 44. ISBN 9783527607495.
-  Archived May 26, 2008, at the Wayback Machine
-  Archived December 26, 2013, at the Wayback Machine
- "United States Patent: 6930119". Patft.uspto.gov. Retrieved 2015-10-11.
-  Archived August 14, 2007, at the Wayback Machine